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Abstract
In recent years, the occurrence of synthetic opioid fentanyl and its derivatives has
grown significantly in forensic casework. This study presents the synthesis and analy-
sis of 18 fentalogs, selected based on information received from local law enforce-
ment. This study provides colorimetric tests, thin-layer chromatography (TLC) which
can potentially be utilized for presumptive screening of the target compounds, as
bulk powders or as trace-level adulterants. The fully validated confirmatory GC–MS
method (employing SIM mode) allows the identification of the 18 derivatives, five
commonly encountered controlled substances and four adulterants, within
20 minutes. The cross-validated method described herein provides a sensitive
screening and quantitation method for the illicit (and potentially harmful) compo-
nents at trace levels (LOD = 0.007–0.822 μg/mL and LOQ = 0.023–2.742 μg/mL
respectively). Spectral data [1H-NMR, 13C-NMR, 19F-NMR, FT-IR, and HRMS] and
assignments for the synthesized reference materials are also provided in the Supple-
mentary Information for laboratories engaged in the routine analysis of fentanyl and
its derivatives.
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1 | INTRODUCTION
Fentanyl (2b) was first patented as an analgesic in 1965 and eventu-
ally reached widespread medical use due to its very strong and fast
action.1,2 However, due to its euphoria-inducing effects resembling
those of heroin (8c), it has also been used recreationally since the
1980s.3,4 From 2013 onward, fentanyl abuse has grown significantly
in the USA, reaching “epidemic levels”.5,6 This situation poses a seri-
ous threat for public health, not just in the USA but potentially world-
wide, as minute quantities of fentanyl could potentially be enough to
induce a lethal overdose. The prevalence of fentanyl analogs or
fentalogs (2a, 2c–2k, 2n–2r, Figure 1), some even more potent than
the original, on drug markets has become a serious issue for law
enforcement and healthcare providers. In the period 2013–2019,
32 new fentalogs were reported to the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA) – with this number growing
every year.7,8 The emergence of fentalogs represents a challenge for
law enforcement, health, and harm reduction practitioners, as the
reporting of extensive chemical information about analogs in aca-
demic journals cannot keep up with the speed at which those
substances appear.5,9 Though principally associated with the United
States, the global significance of these synthetic opioids within foren-
sic casework has been highlighted through a number of toxicological
reports in which fentanyl-laced heroin has been implicated in fatalities
in Canada and Australia.10-12 Though fentanyl and its analogues have
been principally combined with heroin (8c) or are being sold in combi-
nation with U-47700 as “fake Norco” (a formulation of acetamino-
phen and hydrocodone), it has also been detected in street samples of
cocaine (7), and even purportedly sold as 30 ,40-
methylenedioxymethamphetamine (MDMA, 3) – which potentially
may have more serious implications to wider drug using communi-
ties.9,13-19 The development of simple, sensitive methods for the
screening of fentanyl and its analogs at trace level in complex mix-
tures is therefore crucial for public health protection.
Previous studies have reported the analysis of fentanyl (2b) and
its analogs (see Supplementary Information; Table S1). Sisco et al.
have reported a very sensitive direct analysis in real-time mass spec-
trometry [DART-MS, limit of detection = 0.08–0.35 ng] and ion mobil-
ity spectrometry [IMS, limit of detection = 1.0–10.0 ng] screening
methods, but neither of these techniques facilitated efficient
F IGURE 1 Structures of fentanyl
hydrochloride (2b), its derivatives (2a, 2c–2r),
common substances of abuse and adulterants.
Reagents and conditions: (A) RCOCl
(2.0 eq)/iPr2NEt (2.0 eq)/CH2Cl2; (B) HCl (3 M in
cyclopentyl methyl ether, 1.0 eq)/Et2O or acetone
(15–64% yield). See materials and methods
(Section 2.1) for experimental details
separation of the 18 analogs within the study.20 High performance liq-
uid chromatography (HPLC) has been applied in a number of stud-
ies21-23 including one validated method, which has been developed
and utilized to quantify (2b) within bulk forensic samples of heroin.22
Hyphenated techniques (LC–MS, LC-MS2 and UPLC-MS2) have also
been applied to detect fentalogs and their metabolites in blood,24-27
urine25 and wastewater.28 Although these methods are impressively
quick, they were not optimized to chromatographically resolve the
targeted analytes, which can lead to ion suppression when analyzing
low-concentration, adulterated street samples.29 More importantly,
the published method(s) rely on equipment that is prohibitively expen-
sive for smaller forensic laboratories, which normally rely on gas
chromatography–mass spectrometry (GC–MS) as a primary method of
analysis.30 The United Nations Office on Drugs and Crime (UNODC)
have recently published guidelines for the identification and analysis
of (2b) and its analogs – primarily focused on their detection within
biological samples.31 Bravo et al., Strano-Rossi et al., and Misailidi
et al. have also independently developed GC–MS methods for the
determination of (2b),32,33 sufentanil,33 alfentanil,33 2-furanylfentanyl
(2o)34 and ocfentanil34 in toxicological/post-mortem samples, how-
ever, surprisingly simple validated GC–MS methods with the ability to
separate and quantify an array of fentalogs, for the routine analysis of
bulk samples, both in their pure form and in the presence of other
controlled substances or adulterants have not yet been reported in
the literature.
Seeking to address this issue, a general GC-EI-MS screening
method for 18 fentanyl derivatives is reported herein. The selection
of the derivatives, including two novel examples (2l and 2m) reported
herein, was based on the current literature regarding prevalence (see
Supplementary Information Table S2) and information provided by
local law enforcement and public health officials operating within
Greater Manchester, UK. This validated method allows quantification
of the target compounds, in pure form or at trace level in the presence
of common drugs and adulterants. Presumptive methods of detection
(i.e. thin-layer chromatography and colorimetric tests) were also inves-
tigated as a potential tool for the rapid, on-site identification of those
drugs. Additionally, characterization data [1H-NMR, 13C-NMR, 19F-
NMR (for compounds 2l and 2m), FT-IR] for the synthesized reference
material are reported in the Electronic Supplementary Information
and serve as additional comparative information for laboratories
engaged in the routine analysis of fentalogs.
2 | MATERIALS AND METHODS
All reagents were of commercial quality (Sigma-Aldrich, Gillingham,
UK or Fluorochem Limited, Hadfield, UK) and used without further
purification. Solvents (Fisher Scientific, Loughborough, UK) were
dried, where necessary, using standard procedures.35 The target com-
pounds (2a–2r) were synthesized, from 4-ANPP (1), using an adapta-
tion of the method reported by Valdez et al.2 and obtained as stable,
off-white powders (> 99.5% purity by NMR and HRMS). The NMR
purity was calculated using the relative concentration determination
method described by Pauli et al.36 1H-NMR (10 mg/600 μL in d6-
DMSO) and 13C-NMR spectra (20 mg/600 μL in d6-DMSO) were
acquired on a JEOL JMN-ECS-400 (JEOL, Tokyo, Japan) NMR spec-
trometer operating at a proton resonance frequency of 400 MHz and
referenced to the residual solvent peak (d6-DMSO:
1H-NMR
δ = 2.50 ppm, 13C-NMR δ = 39.52 ppm37 respectively). 19F-NMR
spectra (10 mg/600 μL in d6-DMSO containing 0.03% v/v
trifluoroacetic acid, TFA) for compounds (2l, 2m) were acquired on
the same instrument and referenced to TFA (19F-NMR,
δ = −76.55 ppm38). Infrared spectra were obtained in the range
4000–400 cm−1 using a Thermo Scientific Nicolet iS10ATR-FTIR
instrument (Thermo Scientific, Rochester, USA). High-resolution mass
spectrometry (HRMS) data were obtained on an Agilent 6540 LC-
QToF spectrometer in positive electrospray ionization mode. Melting
points were acquired on a Stuart SMP10 digital melting point appara-
tus. The seven seized samples of heroin were provided by Greater
Manchester Police, in accordance with Manchester Metropolitan
University's Home Office license requirements and agreed
procedures.
2.1 | Synthesis
The hydrochloride salts of fentanyl (2b) and its derivatives (2a, 2c–2r)
were prepared as reported by Valdez et al.2 with the following modi-
fications: N-[1-(2-phenylethyl)-4-piperidinyl]aniline (4-ANPP, 1,
1.35 g, 4.8 mmol) was added to dichloromethane (40 mL) and was
treated with diisopropylamine (1.68 mL, 9.6 mmol, 2 eq). The system
was flushed with argon, the mixture cooled in an ice bath and the
appropriate acyl chloride (9.6 mmol, 2 eq) added dropwise. The
resulting solution was stirred at ambient temperature for 2 h. The
mixture was diluted with water (50 mL) and the organic phase
washed sequentially with brine (1 × 50 mL) and saturated aqueous
sodium bicarbonate solution (1 × 50 mL), dried with magnesium sul-
fate, and concentrated in vacuo. The crude oils were purified by
gravity column chromatography (SiO2, 3:7–7:3 v/v EtOAc–hexane).
The free base(s) were dissolved in either diethyl ether or acetone,
and an equimolar amount of hydrogen chloride (3 M in cyclopentyl
methyl ether) was added. The mixture was left to stand for
5–10 minutes and the salt isolated by filtration. The product(s) were
dried in an oven (60C, 12 h) to give white to off-white powders,
which were fully characterized by 1H-NMR, 13C-NMR, 19F-NMR (2l,
2m), FTIR, HRMS, and melting point (see Supplementary Information,
Table S3). Yields of products (based on 4-ANPP, after purification)
were as follows: acetylfentanyl hydrochloride (2a, 33%); fentanyl
hydrochloride (2b, 41%); butyrylfentanyl hydrochloride (2c, 39%),
valerylfentanyl hydrochloride (2d, 30%), hexanoylfentanyl hydrochlo-
ride (2e, 43%); cyclopropylfentanyl hydrochloride (2f, 64%);
cyclobutylfentanyl hydrochloride (2g, 64%); cyclopentylfentanyl
hydrochloride (2h, 37%); cyclohexylfentanyl hydrochloride (2i, 36%);
isobutyrylfentanyl hydrochloride (2j, 60%); isovalerylfentanyl hydro-
chloride (2k, 33%); trifluoroacetylfentanyl hydrochloride (2l, 38%);
pentafluorofentanyl hydrochloride (2m, 52%); methoxyacetylfentanyl
hydrochloride (2n, 29%); 2-furanylfentanyl hydrochloride (2o, 32%),
and phenylfentanyl hydrochloride (2r, 15%).
2.2 | Presumptive tests
Presumptive tests were carried out according to the United Nations
recommended guidelines.39,40 The following standard presumptive
tests were applied in this study: (i) Marquis; (ii) Scott's; (iii) nitric
acid and (iv) Eosin Y tests. The preparation of the reagents and the
test procedure is detailed below. Six repetitive tests of each com-
pound were conducted and negative control samples were used in
all tests.
Marquis test: 1% Formaldehyde (37% aqueous solution) in con-
centrated sulfuric acid (10 mL, d = 1.86 g/mL). Each test sample
(1–2 mg) was placed into a separate dimple well of a white
spotting tile and 2 drops of the test reagent added. Any color
change or other noticeable effect occurring immediately on addition
of the reagents was noted and observations were made again after
5 min.
Scott test: 1% Cobalt (II)thiocyanate in glycerol-deionized water
(1:1, 10 mL). Each test sample (1–2 mg dissolved in 1–2 drops of
methanol) was placed into a separate dimple well of a white spotting
tile and 2 drops of the test reagent added. Any color change or other
noticeable effect occurring immediately on addition of the reagents
was noted and observations were made again after 5 min.
Nitric acid test: Concentrated nitric acid (d = 1.51 g/mL). Each
test sample (1–2 mg) was placed into a separate dimple well of a
white spotting tile and 2 drops of the test reagent added. Any color
change or other noticeable effect occurring immediately on addition
of the reagents was noted and observations were made again after
5 min.
Eosin Y test: 150 μM Eosin Y (20,40,50,70-tetrabromofluorescein)
in aqueous potassium phosphate buffer (pH 7). Each test sample
(1–2 mg) was placed into a separate dimple well of a white
spotting tile and 2 drops of the test reagent added. Any color
change or other noticeable effect occurring immediately on addition
of the reagents was noted and observations were made again after
5 min.
2.3 | Thin layer chromatography (TLC)
Thin layer chromatography (TLC) was carried out on aluminum-backed
SiO2 plates (Merck, Germany). The mobile phase used was
dichloromethane-methanol (9:1 v/v) containing 1% triethylamine. The
developed plate was viewed under UV light (254 nm) and any spots
noted. The plate was sprayed with modified Dragendorff-Ludy-Tenger
reagent,41 the orange spots were marked with a pencil and the reten-
tion factor (Rf), and the relative retention factor (RRf, with respect to
fentanyl, 2b) calculated for each analyte. Six repetitive tests of all
compounds were conducted and negative control samples were used
in all tests. Photographs of the TLC plates for the standards (1, 2a–2r
and 8c) and the seven samples of suspected heroin (SS-1–SS-7) are
provided in the Supplementary Information (Figure S1 and S2,
respectively).
2.4 | Gas chromatography–mass spectrometry
(GC–MS)
GC–MS analysis was performed using an Agilent 7890B GC and a
MS5977B mass selective detector (Agilent Technologies,
Wokingham, UK). The mass spectrometer was operated in the elec-
tron ionization mode at 70 eV. Separation was achieved with a cap-
illary column (HP5 MS, 30 m Å~ 0.25 mm i.d. 0.25 μm) with helium
as the carrier gas at a constant flow rate of 1.2 mL/min. The follow-
ing oven temperature program was used: 175–235C at 30C/min,
hold 7 min, 235–270C at 30C/min, hold 7.5 min, 270–290C at
30C/min, hold 2 min, for a total run time of 20.33 min. A 2 μL ali-
quot of the samples was injected with a split ratio of 50:1. The
injector and the GC interface temperatures were both maintained at
280C respectively. The MS source and quadrupole temperatures
were set at 230C and 150C. Mass spectra were obtained in full
scan mode (50–550 amu). All samples (qualitative analysis) were
prepared as 1 mg/mL solutions in methanol with no derivatization
and analyzed individually and in combination with five commonly
encountered controlled substances (MDMA, 3; cocaine, 7; codeine,
8a; morphine, 8b, and heroin, 8c) and four adulterants (benzocaine,
4a; procaine, 4b; caffeine, 5, and acetaminophen [paracetamol], 6).
Eicosane (0.5 mg/mL) was used as an internal standard and each
sample was injected six times.
2.5 | Calibration standards
Ten mg of each analyte (2a–2r), N-[1-(2-phenylethyl)-4-piperidinyl]
aniline (4-ANPP, 1), 3, 4a, 4b, 5, 6, 7, 8a–8c was weighed accurately
into a 10.0 mL clear glass class A volumetric flask and diluted to vol-
ume with methanol to give a solution containing all components at
1 mg/mL. This solution was then further diluted with methanol and
100 μL of eicosane (50 μg/mL in methanol) added (in each case) to
give calibration standards containing 2.5 μg/mL, 5.0 μg/mL,
10.0 μg/mL, 20.0 μg/mL, and 25.0 μg/mL of each analyte and the
internal standard at 5.0 μg/mL.
2.6 | GC–MS method validation
GC–MS method validation was performed using an Agilent 7890B
GC and a MS5977B mass selective detector (Agilent Technologies,
Wokingham, UK) employing the parameters detailed in Section (2.4).
Mass spectra were obtained under selected ion monitoring (SIM)
mode, using three specific fragment ions for each analyte
(Supplementary Information, Table S3 and S5). The GC–MS method
was validated in accordance with the ICH guidelines42 using the
following parameters: linearity, accuracy, precision (repeatability),
limit of detection (LOD), and limit of quantification (LOQ). Linearity,
precision: six replicate injections of the calibration standards were
performed and the data analyzed under the same conditions. The
%RSD was calculated for each replicate test sample. Accuracy (per-
centage recovery study): determined from spiked samples prepared
in triplicate at three levels over a range of 80–120% of the target
concentration (15 μg/mL). The percentage recovery and %RSD were
calculated for each of the replicate samples. Repeatability (intraday
precision) and intermediate precision (interday precision): deter-
mined from six replicate injections of a spiked sample (10 μg/mL),
analysed on two consecutive days. The percentage purity and
%RSD were calculated for each of the replicate samples. Limits of
detection and quantification: six replicate injections of the calibra-
tion standards were performed and the data analyzed under the
same conditions. The limits of detection and quantification were
determined based on the signal-to-noise (S/N) ratio, where a signal-
to-noise ratio of 3:1 and 10:1 was used to calculate the LOD and
LOQ respectively.42 Signal-to-noise ratios were measured over six
injections in the lower end of the concentration range (2.5 μg/mL
for most analytes; 5.0 μg/mL for morphine) using the auto-root-
mean-squared (Auto-RMS) algorithm from the Agilent MassHunter
Qualitative Analysis software.
2.7 | Test solutions (qualitative GC–MS analysis)
The seven samples of suspected heroin were obtained from Greater
Manchester Police (Manchester, UK; July 2018) and used without
further purification. The individual samples were homogenized and
arbitrarily labelled, SS-1–SS-7, prior to analysis. Each test substance
was weighed accurately (10.0 mg) into a 10.0 mL clear glass class A
volumetric flask, diluted to volume with methanol and filtered. This
solution was then further diluted (8:2, 1.0 mL) with 100 μL methanol
and 100 μL eicosane (50 μg/mL in methanol) added (in each case) to
give a test solution containing ca. 15 μg/mL of the sample and the
internal standard at 5.0 μg/mL. The test solutions were injected in
triplicate and mass spectra were obtained in full scan mode
(50–550 amu).
2.8 | Test solutions (quantitative GC–MS analysis)
Each test substance (SS-1–SS-7) was weighed accurately (12.5 mg)
into a 5.0 mL clear glass class A volumetric flask, diluted to volume
with methanol and then filtered. This solution was then further
diluted (8:2, 1.0 mL) with 100 μL methanol and 100 μL eicosane
(50 μg/mL in methanol) added (in each case) to give a test solution
containing ca. 15 μg/mL of the sample and the internal standard at
5.0 μg/mL. The test solutions were injected in triplicate. Quantifica-
tion of the primary components: caffeine (5), acetaminophen (6),
and heroin (8c) was determined in full scan mode (50–550 amu),
whereas fentanyl (2b) or its analogs (2a, 2c–2r) was determined
using selected ion monitoring (SIM) mode, using three specific frag-
ment ions for each analyte (see Supplementary Information,
Tables S3 and S5).
3 | RESULTS AND DISCUSSION
3.1 | Synthesis
Samples of 18 fentanyl derivatives (see Supplementary Information;
Table S3) were prepared as their corresponding hydrochloride salts.
The selection of the derivatives and inclusion of
trifluoroacetylfentanyl (2l) and pentafluorofentanyl (2m) was based on
the current literature (See Supplementary Information, Table S2) and
information provided by local law enforcement and public health offi-
cials operating in Greater Manchester, UK. The synthesis of the target
compounds was achieved using a modification of the method
reported by Valdez et al.2 from N-[1-(2-phenylethyl)-4-piperidinyl]ani-
line (4-ANPP, 1) and the corresponding acyl chloride, in 15–64% over-
all yield, as stable, white to off-white powders (Figure 1). The
hydrochloride salts were determined to be soluble (10 mg/mL) in
deionized water, methanol, and dimethylsulfoxide and the purity of all
samples was confirmed to be > 99.5% (by NMR and HRMS) in all
cases. The spectral data [1H-NMR, 13C-NMR, 19F-NMR (for com-
pounds 2l and 2m), FT-IR] with assignments for the synthesized refer-
ence material are provided in the Supplementary
Information (Figure S3–S59) for comparison.
3.2 | Thin layer chromatography
Suzuki et al.46 have reported the retention factors (Rf) for 25 fentalogs
including (2a–2c) and (2j). However, under the conditions reported
[SiO2, chloroform-benzene-methanol (10:2:1 v/v/v)] the authors were
unable to fully discriminate these analogs. When thin layer chroma-
tography [SiO2, dichloromethane-methanol (9:1 v/v) containing 1%
triethylamine] was carried out on the 18 derivatives (2a–2r), the spots
produced by each analog gave identical colors (orange) when viewed
with modified Dragendorff-Ludy-Tenger reagent. The TLC data for
each compound, including their retention factor (Rf) and relative
retention factor (RRf, with respect to fentanyl, 2b) and photographs of
the plates are presented in the Supplementary Information (Table S3
and Figure S1). Examination of the Rf values (six replicates) demon-
strated separation of 14 of the compounds based upon this measure,
particularly the cycloalkyl series (2f–2i, Rf = 1.02, 1.05, 1.09, and 1.13,
respectively). Separation was less clear-cut for the other isomeric
derivatives: valerylfentanyl (2d, Rf = 1.06) vs. isovalerylfentanyl (2k,
Rf = 1.09) and 2-furanylfentanyl (2o, Rf = 1.04) vs. 3-furanylfentanyl
(2p, Rf = 1.09). In the case of butyrylfentanyl (2c) and
isobutyrylfentanyl (2j) the two derivatives co-eluted, which is analo-
gous to observations reported by Suzuki et al.46 Though full resolution
of the 18 analogs from 1 (Rf = 0.36) and heroin (8c, Rf = 0.43) was
achieved under these conditions, it was difficult to discriminate
between all 18 analogs by TLC alone and therefore further analysis
was required.
3.3 | Presumptive tests
Kangas et al. have recently disclosed the presumptive testing of fenta-
nyl (2b) in both its pure form or in the presence of either cocaine (7)
or hydrocodone using commercially available NIK-A (Marquis) and
NIK-G (modified Scott's) kits and Eosin Y (20 ,40 ,50,70-
tetrabromofluorescein) dissolved in either phosphate (pH 7) or acetate
(pH 5) buffer.43 Though this study was able to easily discriminate
between the three analytes and demonstrate that Eosin Y could be
employed in the rapid detection of fentanyl (2b), its scope in terms of
detecting other analogs was not explored. The following standard pre-
sumptive color tests were carried out according to the United Nations
recommended guidelines39,40 in this study: (i) Marquis test; (ii) Scott's
test; (iii) Nitric acid test and (iv) Eosin Y test. The results indicated that
all the derivatives (2a–2r), containing a tertiary amine, gave a positive
reaction with the Marquis, Scott's, and Eosin Y reagents (see Supple-
mentary Information; Table S4). These results are in agreement with
Kangas’ observations and infer that Eosin Y has potential for the
detection of a wide range of fentanyl derivatives when used in combi-
nation with the other two reagent tests. In the case of the Scott's
reagent, which is employed in the screening of cocaine, the colored
products are believed to result from the coordination of the tertiary
amines to the pink Co (II) octahedral complex affording the blue Co
(II) tetrahedral complex.40,44 The colored products observed in the
Marquis test may be rationalized by the reaction of the drug mole-
cules with sulfuric acid in a mechanism analogous to that of the reac-
tion of MDMA.40 The concentrated nitric acid test gave negative
reactions with the majority of derivatives except for 2-furanylfentanyl
(2o) and 3-furanylfentanyl (2p) – which produced a pale yellow color
after 5 min – allowing differentiation between them and 4-ANPP (1),
MDMA (3), acetaminophen (5), and the morphine-based opiates (8a–
8c). The positive response of (2o) and (2p) was not readily explained
but may have resulted from electrophilic attack on the furan ring,
potentially facilitating discrimination between these derivatives and
other fentalogs if a secondary screen was required.
The observed color changes (Supplementary Information,
Table S4) indicated that Eosin Y reagent – currently unavailable as a
commercial test kit – could provide a simple and rapid test for these
materials when used in combination with Marquis and Scott's test.
Though other common adulterants and controlled drugs also formed
colored products with the Marquis (3, 8a, 8b, and 8c) and Eosin Y (1,
3, 4b, 5, 6, 7, and 8a–8c) reagent and/or blue Co (II) tetrahedral com-
plexes (4b, 7, and 8c) with Scott's reagent, the observed colors were
significantly different with the Eosin Y to allow for their discrimina-
tion. The recommendation of this study is that three presumptive
tests (Eosin Y, Marquis, and Scott's) could be employed, to discrimi-
nate between controlled drugs and/or adulterants and fentanyl-
derived synthetic opioids, with the nitric acid test used as a secondary
screen in cases where the results are not clear cut.
3.4 | Gas chromatography–mass spectrometry
The qualitative GC–MS method (ca. 20 min) used required an
extremely straightforward solvation of the samples in methanol
(0.1 mg/mL) followed by direct injection into the instrument. No
derivatization step was required. In most cases, the fentanyl deriva-
tives were resolved from each other and five commonly encountered
F IGURE 2 Exemplar
chromatogram demonstrating
separation of 18 fentanyl
derivatives (2a–2r), controlled
substances and relevant adulterants:
3,4-
methylenedioxymethamphetamine
(MDMA, 3), benzocaine (4a),
acetaminophen (6), caffeine (5),
eicosane (internal standard, E),
procaine (4b), cocaine (7), codeine
(8a), morphine (8b), N-[1-(2-
phenylethyl)-4-piperidinyl]aniline (4-
ANPP, 1), and heroin (8c)
[underlined compounds are
common adulterants]. See materials
and methods (Section 2.4) for
experimental details [Colour figure

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































controlled substances (cocaine, codeine, heroin, MDMA, morphine)
and four adulterants (acetaminophen [paracetamol], benzocaine, caf-
feine, and procaine). An exemplar chromatogram is presented in
Figure 2. The use of GC–MS also facilitated the visualization of the
mass spectral data for each individual compound, and these are pres-
ented in Figure 1. In the case of the two co-eluting derivatives (2f and
2n, tR = 13.6 min), differentiation was achieved through direct com-
parison of the mass spectral data. Though both derivatives underwent
primary α,β-cleavage of the phenethylamine moiety, the resulting base
peaks (2f, m/z = 257 vs. 2n, m/z = 261) and subsequent fragmentation
patterns were significantly different.45 In the case of (2f) secondary
cleavage of the base peak (m/z = 257) via scission of either the piperi-
dine ring or the amide group gave rise to two fragments (m/z = 214
and m/z = 189, respectively), which underwent further dissociation
affording the fragment (m/z = 146) common to many fentanyl-type
opioids (Figure 2).46 The electron ionization (EI) mass spectrum for
methoxyacetylfentanyl (2n) included fragment ions at m/z = 261 (base
peak), 218, 190, 158, 91, and 45 (C2H5O
+), which correspond to the
data obtained by Jannetto et al.45 Clear discrimination of the co-
eluting derivatives was achieved using selected ion monitoring (SIM),
employing three distinct ions for each analyte (2f, m/z = 257.1, 189.1,
and 146.0; 2n, m/z = 261.1, 218.0, and 158.0). The two partially
resolved analytes (2h, tR = 17.2 min and 2o, tR = 17.3 min) were also
discriminated using SIM mode (2h, m/z = 285.1, 189.1, and 146.0
vs. 2o, m/z = 283.1, 240.0, and 95.0) and both underwent EI fragmen-
tation analogous to other fentanyl-derived opioids, affording fragment
ions which were in agreement with the literature (Figure 2).46
A number of groups have reported utilizing HPLC21-23 or GC–
MS32-34 for the toxicological screening of fentanyl (2b) and its deriva-
tives within bulk powders and biological matrices with a recent report
disclosing the development of a high performance liquid chromato-
graphic method employing amperometric detection (HPLC-AD).22
Despite being able to detect [LOD = 0.45–2.93 μg/mL] and quantify
[LOQ = 1.49–9.76 μg/mL] 11 fentalogs (2a–2d, 2f–2h, 2j–2k, 2n, and
2r), the method utilized a specialized sensing platform and lacked
selectivity for heroin (8c) vs. cocaine (7) and the two common adulter-
ants (caffeine, 5 and acetaminophen, 6), normally found in seized bulk
samples. Interestingly, though GC–MS methods are routinely
employed by forensic laboratories for both the identification and
quantification of drugs of abuse, no validated quantitative GC–MS
methods that provide simple general screening and quantification of
the components in bulk samples have, to date, been reported. The
quantitative GC–MS method (SIM mode), using three ions specific to
each analyte (Supplementary Information, Table S3), was developed
and validated in accordance with the ICH guidelines.42 To facilitate
accurate identification of the compounds present within seized sam-
ples the ion ratios (relative to the base peak) for the three ions specific
to each analyte were determined. The accuracy (%RSD) of the ion
ratios was calculated from three injections of each analyte and
showed 0.3–7.7% variation between replicates (Supplementary Infor-
mation, Table S5). Calibration standards were prepared and all
18 substituted fentalogs demonstrated a linear response
(r2 = 0.997–0.999) over a 2.5–25.0 μg/mL range with satisfactory
repeatability (RSD = 0.3–4.5%, n = 6). Due to the level of sensitivity
required for the detection of the fentanyl analogs within bulk samples
the limits of detection (LOD) and quantification (LOQ) were deter-
mined for both scan mode and selective ion monitoring mode (see
Supplementary Information, Table S6). In scan mode the LOD/LOQs
were determined to be ~100× less sensitive and as such the selective
ion monitoring mode was deemed more suitable for this application.
The limits of detection and quantification for the analytes (in bulk
samples) were determined (for SIM mode), based on the signal to
noise (S/N) ratio, as being 0.008–0.125 and 0.025–0.415 μg/mL,
respectively, which is ~50× more sensitive than the recently published
HPLC-AD method. The method was also suitable for the detection
and quantification of the five commonly encountered controlled sub-
stances [cocaine, codeine, heroin, MDMA, and morphine] and four
adulterants [acetaminophen (paracetamol), benzocaine, caffeine, and
procaine], demonstrating linear response (r2 = 0.992–0.999) over the
same concentration range with reasonable repeatability
(RSD = 0.7–6.9%, n = 6). The limits of detection and quantification
TABLE 2 Qualitative and quantitative analysis of seized samples






SS-1 0.07 Acetaminophen (6), 5.9 ± 0.5% w/w;
Caffeine (5), 3.69 ± 0.06% w/w
Heroin (8c), 53.1 ± 0.8% w/w; fentanyl
(2b), 6.29 ± 0.01% w/w
SS-2 0.12 Acetaminophen (6), 26.8 ± 1.5% w/w;
Caffeine (5), 14.8 ± 0.8% w/w
Heroin (8c), 20.5 ± 0.8% w/w; fentanyl




SS-3 0.11 Acetaminophen (6), 27.1 ± 0.6% w/w;
Caffeine (5), 16.9 ± 0.7% w/w




SS-4 0.73 Acetaminophen (6), 28.6 ± 2.0% w/w;
Caffeine (5), 20.5 ± 1.3% w/w




SS-5 1.04 Heroin (8c), 82.9 ± 2.7% w/w
Minor component:
6-mono-acetylmorphine (10)
SS-6 0.95 Heroin (8c), 74.7 ± 1.6% w/w
Minor component:
6-mono-acetylmorphine (10)
SS-7 0.15 Heroin (8c), 82.2 ± 3.1% w/w
Minor component:
6-mono-acetylmorphine (10)
aKey: Component only detected in SIM mode.
were determined for the controlled substances and adulterants, and
found to be 0.007–0.822 and 0.023–2.742 μg/mL, respectively
(Table 1). The accuracy (percentage recovery study) of the assay was
determined from spiked samples prepared in triplicate at three levels
over a range of 80–120% of the target concentration (15 μg/mL). The
repeatability (%RSD) of the method and the percentage recovery (%
assay) for each of the three replicate samples demonstrated good
recoveries (100 ± 3%) for all 18 analytes within the desired concentra-
tion range (Supplementary Information, Table S7). The precision
(inter- and intraday precision) was calculated from six replicate injec-
tions of a spiked sample (10 μg/mL) representing 100% of the test
concentration, analysed on two consecutive days (Supplementary
Information, Table S8). In most cases the inter- and intraday precision
was within acceptable limits (100 ± 2%), except for 4b (95.9% after
24 h) and 8c (95.0% after 24 h), which may result from hydrolysis of
the analytes. The GC–MS method and its validation parameters are
summarized in Table 1 and Tables S5–S8 (Supplementary Information)
were deemed suitable for the routine analysis of the seven street
samples.
3.5 | Forensic application
Seven bulk samples (SS-1–SS-7) were obtained from Greater Man-
chester Police (Manchester, UK, December 2018), weighed between
0.07–1.04 g and were suspected to contain heroin (8c). The samples
varied in color from light brown to dark beige, which potentially indi-
cates them originating from either Southwest Asia or Columbia.47
F IGURE 3 EI-MS spectra of acetylfentanyl hydrochloride (2a); fentanyl hydrochloride (2b); butyrylfentanyl hydrochloride (2c), valerylfentanyl
hydrochloride (2d), hexanoylfentanyl hydrochloride (2e); cyclopropylfentanyl hydrochloride (2f); cyclobutylfentanyl hydrochloride (2g);
cyclopentylfentanyl hydrochloride (2h) and cyclohexylfentanyl hydrochloride (2i); isobutyrylfentanyl hydrochloride (2j); isovalerylfentanyl
hydrochloride (2k); trifluoroacetylfentanyl hydrochloride (2l); pentafluorofentanyl hydrochloride (2m); methoxyacetylfentanyl hydrochloride (2n);
2-furanylfentanyl hydrochloride (2o), and phenylfentanyl hydrochloride (2r)
Preliminary presumptive tests were carried out according to the pro-
cedures reported herein. The seven samples (SS-1–SS-7) gave positive
reactions with the Marquis (brown-purple) test potentially indicating
the presence of heroin (8c) or another opioid, but the inherent color
of the sample matrix made positive identification difficult. Only one of
the samples (SS-1) gave a positive reaction with Eosin Y (deep pink)
potentially indicating the presence of fentanyl (2b) or a structural ana-
log. However, at low concentrations, a color change indicating a posi-
tive response may have been obscured by the inherent color of the
matrix. The seven samples gave inconclusive results with both Scott's
reagent and concentrated nitric acid and no inference could be made
on the substances that may have been present – demonstrating the
limitation of colorimetric testing for samples of this nature. Thin layer
chromatographic (TLC) analysis of the seven samples was performed
and comparison of the samples with the reference materials con-
firmed the presence of heroin (8c, Rf = 0.22) in all seven samples. All
seven samples (SS-1–SS-7) showed significant levels of adulteration,
however, the principal component was determined to be heroin (8c,
Rf = 0.22) and one sample (SS-1) potentially indicated the presence of
fentanyl (2b, Rf = 0.46) (see Supplementary Information, Figure S2).
Preliminary FT-IR analysis indicated the presence of heroin (ester
C=O bands at ~1756 and ~1727 cm−1) in all seven samples (see Sup-
plementary Information, Figure S60–S66). Detailed examination of
the spectral bands (amide C=O band at ~1644 cm−1) potentially indi-
cated the presence of fentanyl (2b) in only one of the seven samples
(SS-1) (see Supplementary Information, Figure S60).
Qualitative GC–MS analysis (scan mode) corroborated the pre-
sumptive tests and confirmed the presence of heroin (8c, tR = 11.1 min,
m/z = 369.2, 327.2 [base peak], and 268.1) in all seven samples, with
three (SS-5–SS-7) containing heroin as the single component (see
Supplementary Information, Figure S67). The remaining samples (SS-
1–SS-4), were determined to contain heroin, caffeine (5, tR = 3.0 min,
m/z = 194.1, 109.0, 82.0) and acetaminophen (6, tR = 2.4 min,
m/z = 151.0, 109.0, 80.0) as the primary adulterants. Three samples
F IGURE 4 Proposed fragmentation patterns for fentanyl derivatives (2f, 2h, 2n, and 2o)
(SS-2–SS-4) contained additional (minor) peaks, which were deter-
mined to be N,O-diacetylaminophenol (DAAP, tR = 2.6 min,
m/z = 193.0, 151.0, and 109.0) and six (SS-2–SS-7) contained
6-mono-acetylmorphine (6-MAM, tR = 9.9 min, m/z = 327.1, 268.1,
and 215.0). N,O-diacetylaminophenol has been observed to form via
transacetylation between acetaminophen (6) and o-acetylsalicylic acid
(aspirin) combinations that have been stored for prolonged periods48
and may have arisen, in these samples, from a similar interaction
between (6) and (8c). The presence of hydrolysis product 6-MAM is
postulated to arise if heroin samples are stored in damp conditions
over a period of time.49 One sample (SS-1, Supplementary
Information Figure S67A) indicated the presence of fentanyl (2b,
tR = 12.0 min, m/z = 245.1, 189.1, 146.0), which agreed with the pre-
liminary tests carried out on this sample.
With substantial evidence supporting a GC–MS approach for
quantifying fentalogs in heroin street samples, the applicability of the
optimized quantification method was tested. The samples were rea-
nalyzed (in triplicate) using the validated GC–MS method at a concen-
tration of 15 μg/mL. Quantification of the primary components
(caffeine (5), acetaminophen (6), and heroin (8c)) was performed in full
scan mode (50–550 amu), whereas analysis of fentanyl (2b) or its ana-
logs (2a, 2c–2r) was performed in SIM mode, using three specific frag-
ment ions for each analyte (Table 1). The quantitative GC–MS results
confirmed that all seven samples contained heroin (tR = 11.1 min, 8c)
at levels ranging between 17.8–82.9% w/w, with the lower purity
samples (SS-1–SS4) containing significant levels of the commonly
used diluents caffeine (5, 3.7–20.5% w/w) and acetaminophen (6,
5.9–28.6% w/w) (Table 5).50
As preliminary analysis of SS-1 (0.07 g) (Figure 3A) indicated the
presence of fentanyl (2b, tR = 11.9 min), it was necessary to quantify
it and the other components, using our validated GC–MS (SIM)
method. Selective ion monitoring using the characteristic ions
(m/z = 245.1, 189.1, 146.0) (Figure 3E) indicated that the sample con-
tained 6.29 ± 0.01% w/w (n = 3) of (2b), equating to
4.403 ± 0.007 mg within the bulk sample (Figure 3B). Interestingly,
though preliminary testing and GC–MS analysis obtained in full scan-
mode (Figure 3C) did not indicate the presence of any fentanyl deriva-
tives within sample SS-2 (0.12 g), selective ion monitoring (SIM)
(Figure 3D) revealed that the sample did indeed contain (2b) at a level
of 0.288 ± 0.008% w/w (n = 3) equating to 0.35 ± 0.01 mg within the
bulk sample. Relative ion intensities for (2b) were within the tolerance
windows prescribed by the World Anti-Doping Agency guidelines
when compared with the pure reference material (see Supplementary
Information, Table S5) further confirmed our assertion of the presence
of fentanyl (2b) within the two samples (SS-1 and SS-2).51 It is impor-
tant to note that due to the small sample size (n = 7), the results pres-
ented herein may not truly reflect the typical prevalence of heroin
samples that contain fentanyl nationally, however, these results
F IGURE 5 Comparison of qualitative GC–
MS analysis, of seized heroin bulk samples
(SS-1 and SS-2, 0.1 mg/mL in methanol) using
full scan and selective ion monitoring modes:
(A) GC chromatogram (full scan mode) for SS-
1; (B) GC chromatogram (selective ion
monitoring mode; m/z = 245.1, 189.1, 146.0)
for SS-1; (C) GC chromatogram (full scan
mode) for SS-2 (C) GC chromatogram
(selective ion monitoring mode; m/z = 245.1,
189.1, 146.0) for SS-2; (D) SIM spectrum of
peak (tR = 12.0 min) corresponding to fentanyl
(2b) [Colour figure can be viewed at
wileyonlinelibrary.com]
demonstrate that the 20 minute GC–MS method, employing selective
ion monitoring described herein is potentially suitable for the routine
screening of suspect samples, which may contain fentanyl (or its
derivatives) at trace levels.
4 | CONCLUSIONS
We have presented the synthesis of 18 fentalog reference materials,
including two novel derivatives (2l and 2m), selected based on infor-
mation received by local public health officials operating in the
Greater Manchester region and cross-validated the presumptive and
confirmatory methods presented herein with seven samples obtained
from local law enforcement. Colorimetric tests and thin layer chroma-
tography provided a quick, presumptive detection of these com-
pounds – however, the complex nature and matrix effects associated
with adulterated samples potentially limit their application. The fully
validated GC–MS method (employing SIM mode) allowed the separa-
tion and identification of all 18 fentanyls, five commonly encountered
controlled substances [cocaine, codeine, heroin, MDMA, and mor-
phine] and four adulterants [acetaminophen (paracetamol), benzo-
caine, caffeine, and procaine] within 20 minutes. When applied to
seized samples, the validated method allowed sensitive screening and
quantitative analysis of the illicit (and potentially harmful) ingredients
at trace levels. Additionally, characterization data [1H-NMR, 13C-
NMR, 19F-NMR (for compounds 2l and 2m), FT-IR and HRMS] for the
synthesized reference materials are reported in the Electronic Supple-
mentary Information and serve as additional comparative information
for laboratories engaged in the routine analysis of existing and novel
fentalogs.
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